2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Pathology, Bioinformatics, Treatment Considerations, Combination Therapy, Non-Biological Therapies, Chemotherapy, Clinical Practice (Health Services and Quality), Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Measurable Residual Disease, Research, AML, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly
PAPER

5245 Peripheral blood WT1 monitoring as a practical warning biomarker for relapse risk in acute myeloid leukemia

Augustin Boudry, Nicolas Duployez, MD2, Sylvain Chantepie, MD3, Alice Marcau4, Juliette Lambert5, Elise Fournier6, Thomas Cluzeau, MD, PhD7, Anne Bouvier, PhD, PharmD8, Delphine Lebon, MD, PhD9, Cecile Pautas10, Madalina Uzunov, MD11, Jean-Valère Malfuson, MD12, Pascal Turlure13, Kevin-James Wattebled14, Thorsten Braun, MD, PhD15, Céline Berthon16, Iona Vaida17, Jamilé Frayfer18, Sabine Tricot19, Celia Salanoubat20, Isabelle Plantier21, Stéphane de Botton, MD, PhD22, Corentin Orvain, MD PhD23, Regis Peffault De Latour, MD, PhD24, Christian Recher25, Herve Dombret Sr, MD26, Raphael Itzykson, MD, PhD27, Hunault-Berger Mathilde, MD, PhD28, Claude Preudhomme, PhD29
1 Laboratoire d’Hématologie, Centre de Biologie-Pathologie, CHU de Lille, Université de Lille, Inserm U1366, CRCLille, Lille, France
2 Laboratoire d’Hématologie, Centre de Biologie-Pathologie, CHU de Lille, Université de Lille, Inserm U1366, CRCLille, Lille, France
3 Institut d’Hématologie de Basse-Normandie, CHU de Caen Normandie, Caen, France
4 Laboratoire d’Hématologie, Centre de Biologie-Pathologie, CHU de Lille, Université de Lille, Inserm U1366, CRCLille, Lille, France
5 Department of Hematology, Centre Hospitalier de Versailles, Le Chesnay-Rocquencourt, France
6 Laboratoire d’Hématologie, Centre de Biologie-Pathologie, CHU de Lille, Université de Lille, Inserm U1366, CRCLille, Lille, France
7 Service d’Hématologie clinique, CHU de Nice, Université Côte d’Azur, Nice, France
8 Laboratoire d’Hématologie, CHU d’Angers, Université d’Angers, Angers, France
9 Service d’Hématologie clinique et de Thérapie cellulaire, CHU Amiens-Picardie, Amiens, France
10 Service d’Hématologie clinique, Hôpital Henri-Mondor, AP-HP, Université Paris-Est Créteil, Créteil, France
11 Service d’Hématologie clinique, Hôpital Pitié-Salpêtrière, AP-HP, Sorbonne Université, Paris, France
12 Service d’Hématologie, Hôpital d’Instruction des Armées Percy, Clamart, France
13 Service d’Hématologie clinique et de Thérapie cellulaire, CHU de Limoges, Limoges, France
14 Service d’Hématologie, Centre hospitalier de Dunkerque, Dunkerque, France
15 Service d’Hématologie clinique, Hôpital Avicenne, AP-HP, Université Sorbonne Paris Nord, Bobigny, France
16 Service des Maladies du sang, CHU de Lille, Université de Lille, Lille, France
17 Service d’Hématologie, Centre hospitalier René-Dubos, Pontoise, France
18 Service d’Hématologie, Grand Hôpital de l’Est Francilien, site de Meaux, Meaux, France
19 Service d’Hématologie, Centre hospitalier de Valenciennes, Valenciennes, France
20 Service d’Hématologie clinique, Centre hospitalier Sud Francilien, Corbeil-Essonnes, France
21 Service d’Hématologie, Centre hospitalier de Roubaix, Roubaix, France
22 Département d’Hématologie, Gustave Roussy, Université Paris-Saclay, Villejuif, France
23 Service des Maladies du Sang, CHU d’Angers, Université d’Angers, Angers, France
24 Service des Maladies du Sang, CHU d’Angers, Université d’Angers, Angers, France
25 Service d’Hématologie, Institut universitaire du cancer de Toulouse-Oncopole, CHU de Toulouse, Université Toulouse III – Paul-Sabatier, Toulouse, France
26 Coordination ALFA, Paris, France
27 Service d’Hématologie adultes, Hôpital Saint-Louis, AP-HP, Université Paris Cité, Paris, France
28 Service des Maladies du Sang, CHU d’Angers, Université d’Angers, Angers, France
29 Laboratoire d’Hématologie, Centre de Biologie-Pathologie, CHU de Lille, Université de Lille, Inserm U1366, CRCLille, Lille, France

Introduction: Measurable residual disease (MRD) is a major determinant of outcome in acute myeloid leukemia (AML). Although Wilms’ tumor 1 (WT1) overexpression has long been proposed as a broadly applicable molecular MRD marker, its limited specificity and variable background expression have restricted its clinical adoption. Nevertheless, its low cost, easy standardization, minimal invasiveness, and feasibility on peripheral blood (PB) make WT1 an attractive candidate for longitudinal monitoring, warranting reassessment of its prognostic value in contemporary AML practice which incorporates genetics-informed risk stratification and advanced MRD strategies.

Methods: We analyzed PB WT1 MRD monitoring in adults aged 18–60 years with newly diagnosed AML treated intensively in the prospective, multicenter French Backbone Intergroup (BIG-1) trial (NCT02416388). Among 2,023 patients, WT1 expression assessment at diagnosis was not mandatory but was performed in 402 patients, of whom 364 showed WT1 overexpression (90%). Patients assessed for WT1 expression were comparable to the 1,621 patients who were not assessed in terms of baseline characteristics.  WT1 positivity during treatment was defined as a PB WT1/ABL1 ratio × 100 ≥0.5%, according to the standardized European LeukemiaNet assay described by Cilloni et al. (JCO 2009).Prognostic analyses were restricted to patients in first complete remission. Outcomes were evaluated after one course (MRD1; n=259), 2 courses of chemotherapy (MRD2, n=218), and prior to allogeneic hematopoietic cell transplantation (n=180). Cumulative incidence of relapse (CIR), relapse-free survival (RFS), and overall survival (OS) were compared according to WT1 status. Multivariable models were adjusted for FLT3-ITD, NPM1 mutation, poor-risk cytogenetics and allogeneic transplantation in first complete remission as a time-dependent covariate.

Results: WT1 positivity was observed in 75/259 patients (29%) at MRD1, 24/218 patients (11%) at MRD2, and 23/180 patients (13%) before transplantation. Among the 66 patients who were WT1-positive at MRD1 and evaluable at MRD2, 34 (51.5%) became WT1-negative, 15 (22.7%) remained positive without an increase in WT1 levels, and 17 (25.8%) showed an increase in WT1 levels at MRD2. At MRD1, WT1 positivity was associated with inferior RFS (p=0.025) and OS (p=0.035), while CIR did not differ significantly (p=0.133). At MRD2, WT1 positivity was associated with higher CIR (p=0.029) and inferior RFS and OS (both p<0.001). In the pre-transplant setting, WT1 positivity was associated with higher CIR (p=0.014) and inferior RFS and OS (both p<0.001). In multivariable models, the MRD1 signal remained strongest for OS (HR 1.90, 95% CI 1.28-2.81; p=0.001), with nonsignificantly higher CIR and inferior RFS (sHR 1.48, p=0.105; HR 1.45, p=0.064). At MRD2, WT1 positivity remained associated with higher CIR (sHR 2.23, p=0.023), inferior RFS (HR 2.81, p<0.001), and inferior OS (HR 3.92, p<0.001). Within the 6-8 weeks pre-transplant analysis, with follow-up starting at the pre-transplant assessment, WT1 positivity was again associated with higher CIR (sHR 2.63, p=0.008), inferior RFS (HR 3.24, p<0.001), and inferior OS (HR 3.86, p<0.001).

Conclusions: In this large AML cohort, peripheral blood WT1 persistence after treatment was reproducibly associated with relapse risk and survival across successive treatment landmarks, with the strongest signal observed at MRD2 and before transplantation. The weaker prognostic signal at MRD1 may reflect the limited sensitivity and specificity of WT1 after the first course of chemotherapy, as WT1 negativity does not exclude residual disease detectable by more sensitive MRD methods, whereas WT1 positivity may partly result from hematopoietic regeneration. Persistent WT1 expression at later treatment landmarks appears to provide greater clinical discrimination, likely enriching for patients with the highest levels of residual disease below morphologic detection and therefore at increased risk of relapse. Although WT1 is less specific than leukemia-specific MRD assays such as UHS-NGS or MFC, its simplicity, low cost, and peripheral blood feasibility support a pragmatic role as a warning biomarker to identify patients who require closer monitoring and further investigation with more advanced MRD methodologies, as well as possible more intensive therapeutic intervention when possible. These data support a nuanced reappraisal of WT1 monitoring in AML.

Claude Preudhomme, PhD: No relevant conflicts of interest to declare.